Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: KW-6356
Drug: Clarithromycin
Drug: Rifampicin

First Posted Date: 2019-08-28

Last Posted Date: 2019-11-29

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT04070495

Locations: 🇯🇵
Medical Co. LTA Sumida Hospital, Sumida-ku, Tokyo, Japan

A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 894416
Drug: Rifampicin

First Posted Date: 2019-08-19

Last Posted Date: 2023-08-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT04060719

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib

Phase 1

Completed

Conditions: Healthy Male Subjects

Interventions: Drug: Fluzoparib
Drug: Rifampicin

First Posted Date: 2019-07-08

Last Posted Date: 2020-02-26

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT04011124

Locations: 🇨🇳
First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: pamiparib 60 mg
Drug: pamiparib 20 mg
Drug: pamiparib
Drug: rifampin
Drug: itraconazole

First Posted Date: 2019-06-21

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 25

Registration Number: NCT03994211

Locations: 🇬🇪
Arensia Exploratory Medicine Llc, Tbilisi, Georgia
🇵🇱
Szpital Luxmed, Warszawa, Poland
🇸🇰
Summit Clinical Research, Sro, Bratislava, Slovakia

and more 1 locations

Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: rifampin
Drug: itraconazole
Drug: mitapivat sulfate

First Posted Date: 2019-06-19

Last Posted Date: 2019-10-23

Lead Sponsor: Agios Pharmaceuticals, Inc.

Target Recruit Count: 28

Registration Number: NCT03991312

Locations: 🇺🇸
Celerion, Inc, Tempe, Arizona, United States

Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Fedratinib
Drug: Rifampin
Drug: Efavirenz

First Posted Date: 2019-06-12

Last Posted Date: 2020-08-21

Lead Sponsor: Celgene

Target Recruit Count: 32

Registration Number: NCT03983239

Locations: 🇺🇸
Covance Clinical Research Unit Inc - Dallas, Dallas, Texas, United States

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-788
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2019-04-26

Last Posted Date: 2020-08-21

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT03928327

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subject

Interventions: Drug: Saline
Drug: ACT-246475
Drug: Rifampicin

First Posted Date: 2019-01-23

Last Posted Date: 2022-11-16

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 14

Registration Number: NCT03814200

Locations: 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands

Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin

Phase 1

Completed

Conditions: Drug Interaction Potentiation

Interventions: Drug: vadadustat
Drug: Cyclosporins
Drug: Probenecid
Drug: Rifampin

First Posted Date: 2019-01-11

Last Posted Date: 2019-03-22

Lead Sponsor: Akebia Therapeutics

Target Recruit Count: 40

Registration Number: NCT03801746

Locations: 🇨🇦
inVentiv Health Clinique Inc., Québec City, Quebec, Canada

A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Itraconazole
Drug: Verapamil
Drug: Rifampicin
Drug: Midazolam
Drug: RV521
Drug: Placebo for RV521

First Posted Date: 2018-12-20

Last Posted Date: 2024-04-22

Lead Sponsor: Pfizer

Target Recruit Count: 82

Registration Number: NCT03782662

Locations: 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy